Trial Profile
Randomized Phase 2 Study Of Cisplatin/Pemetrexed With Or Without Axitinib (AG-013736) As First-Line Treatment For Patients With Non-Squamous Non-Small Cell Lung Cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Jul 2019
Price :
$35
*
At a glance
- Drugs Axitinib (Primary) ; Cisplatin; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Pfizer
- 05 Jun 2012 Results presented at the 48th Annual Meeting of the American Society of Clinical Oncology.
- 10 Apr 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 29 Mar 2012 Planned end date changed from 1 Feb 2012 to 1 Mar 2012 as reported by ClinicalTrials.gov.